Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 943 results for "bristol"

Fri 28th Nov 7:30pm - Sky Bet League 1 Peterboro vs Bristol C

Previous lineup from Peterborough United vs Swindon Town on Saturday 22nd November 2014. Please come back closer to kick-off for live team news. Starting XI 27 Alnwick 2 Smith 22 Santos 21 Burgess 3 Ntlhe 19 Mendez-Laing ... Sky Sports, 1 hour ago

5,284 images for bristol

Business Leader, 2 days ago
One News Page United Kingdom, 2 hours ago
Colchester United, 1 hour ago
One News Page United Kingdom, 6 hours ago
One News Page United Kingdom, 5 hours ago
One News Page United Kingdom, 7 hours ago
One News Page United Kingdom, 6 hours ago
One News Page United Kingdom, 10 hours ago
Bristol City, 1 day ago
One News Page United Kingdom, 19 hours ago
Miami Herald

Hepatitis C drug meant to rival Gilead blocked by FDA

U.S. regulators have declined to approve Bristol-Myers Squibb's daclatasvir as part of a combination hepatitis C treatment with another antiviral drug called asunaprevir. The company said Wednesday that data it submitted to the Food and Drug ...
 SiliconValley.com4 hours ago Bristol-Myers: FDA blocks hepatitis C drug for now  Yahoo! UK and Ireland5 hours ago BRISTOL MYERS SQUIBB : Recent Findings in Hepatitis C Virus Described by Researchers from Bristol-Myers Squibb (All-oral daclatasvir plus asunaprevir for hepatitis C virus...  4 Traders3 hours ago FDA blocks hepatitis C drug for now  Japan Today2 hours ago
Pharma Letter

Bristol-Myers Squibb Receives Complete Response Letter from U.S. Food and Drug Administration for Daclatasvir, an Investigational Treatment for Hepatitis C

Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for daclatasvir, an NS5A complex inhibitor, in combination ...
 Stockwatch8 hours ago Bristol-Myers, Five Prime Therapeutics Enter Into Clinical Collaboration Deal  RTTNews.com2 days ago Bristol-Myers Squibb partners with Five Prime on immunotherapy combination trials24-11-2014  Pharma Letter2 days ago Five Prime hitches onto Bristol-Myers' blockbuster-in-waiting immunotherapy  FierceBiotech2 days ago
Sky Sports

Reid returns to Plymouth

Bobby Reid has returned to Plymouth Argyle for a second spell following a loan move from Bristol City. The 21-year-old midfielder played seven games for the Pilgrims earlier in the season before he was recalled by his parent club to cover an injury ...
 Sky Sports3 hours ago Duo set for Bristol City exit  Sky Sports7 hours ago Bristol City's Reid back at Argyle  BBC9 hours ago Reid to return to Plymouth Argyle  BBC9 hours ago
Sky Sports

El-Abd loaned to Bury

Bury have bolstered their defensive options by bringing in centre-half Adam El-Abd on loan from Bristol City until January 25. The 30-year-old Egyptian joined the Robins from Brighton in January, playing 13 times for City last season and making six ...
 Sky Sports6 hours ago Bury bring in El-Abd and Milsom  BBC8 hours ago

Bristol Myers (BMY) Trading Near $57.72 Support Level

The patented option-trade picking algorithms that power's Artificial Intelligence Center are highlighting two trades on Bristol-Myers Squibb Co ("BMY) today after it ...
 Individual.com3 hours ago

Five Prime Therapeutics Up on Deal with Bristol-Myers

Five Prime Therapeutics, Inc. ( FPRX ) surged 31.4% after the company announced that it has entered into an agreement with Bristol-Myers Squibb Company ( BMY ). Overall, the stock has gained 28.6% to date. The companies have entered into an ...
 Yahoo! Finance3 hours ago
Fast Company

The "Number Two" Bus Runs On--What Else?--Human Waste

The new Bio-Bus in Bristol, England, is nicknamed "the number two" for a reason: It runs on fuel made from human waste. The biogas in the bus's tank is also made from food waste. Ironically, powering a bus with poop can actually help a city smell ...
 Fast Company7 hours ago UK's first bus powered by food and human waste hits Bristol roads  NGV Journal1 day ago First Poo Bus Gets to Work in Bristol  ETeknix.com3 days ago UK's first 'poo-fuelled' bus takes new road to sustainable future  Business Standard5 days ago

Bristol-Myers gets CRL for daclatasvir NDA

News Editor The FDA issues a Complete Response Letter (CRL) to Bristol-Myers Squibb (BMY +0.2%) in response to its NDA for HCV drug daclatasvir in combination with other agents. The company's initial daclatasvir NDA focused on its use in ...
 Seeking Alpha7 hours ago Bristol-Myers' (BMY) Daclatasvir Delay a Positive for Achillion (ACHN), FBR Capital Says  Financial Content6 hours ago Five Prime Therapeutics' (FPRX) Bristol-Myers Collaboration Validates Thesis, BMO Capital Says  Financial Content2 days ago Bristol-Myers Squibb (BMY) Receives Complete Response Letter from FDA for Daclatasvir NDA  Financial Content7 hours ago

FDA declines to approve Bristol-Myers hepatitis drug

Nov 26 (Reuters) - Bristol-Myers Squibb Co on Wednesday said U.S. regulators had declined to approve use of its experimental daclatasvir drug for hepatitis C, in combination with other antiviral drugs. Bristol-Myers said it had initially sought ...
 CNBC7 hours ago No En Banc Review for Use of Post Invention Information in Obviousness Analysis  National Law Review4 hours ago Bristol-Myers Hepatitis C Drug Needs More Data on Combinations  Bloomberg5 hours ago UPDATE 1-FDA declines to approve Bristol-Myers hepatitis drug  Reuters6 hours ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - bristol
Get updated on latest news & your favorite topics right in your inbox!
More     Less